BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 35130342)

  • 21. [Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia].
    Fukuoka K; Tsumura Y; Noguchi J; Sugawa M; Takaki T; Hiraki T; Inoue K; Mitani Y; Tomita O; Oshima K; Yanagi M; Isobe K; Mori M; Arakawa Y; Koh K
    Rinsho Ketsueki; 2020; 61(4):322-326. PubMed ID: 32378574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel approach for relapsed/refractory FLT3
    Li KX; Wu HY; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Yang DH; Huang YX
    Mol Cancer; 2022 Mar; 21(1):66. PubMed ID: 35246156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.
    Reed DR; Sen JM; Pierce EJ; Elsarrag RZ; K Keng M
    J Oncol Pharm Pract; 2020 Jul; 26(5):1200-1212. PubMed ID: 32338136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.
    Daver N; Venugopal S; Ravandi F
    Blood Cancer J; 2021 May; 11(5):104. PubMed ID: 34045454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.
    Lee JK; Chatterjee A; Scarpa M; Bailey CM; Niyongere S; Singh P; Mustafa Ali MK; Kapoor S; Wang Y; Silvestri G; Baer MR
    Cancer Res Commun; 2024 Feb; 4(2):431-445. PubMed ID: 38284896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
    Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S
    Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
    Numan Y; Abdel Rahman Z; Grenet J; Boisclair S; Bewersdorf JP; Collins C; Barth D; Fraga M; Bixby DL; Zeidan AM; Yilmaz M; Desai P; Mannis G; Deutsch YE; Abaza Y; Dinner S; Frankfurt O; Litzow M; Al-Kali A; Foran JM; Sproat LZ; Jovanovic B; Daver N; Perl AE; Altman JK
    Am J Hematol; 2022 Mar; 97(3):322-328. PubMed ID: 34981560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
    Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
    Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful bridge therapy of gilteritinib to cord blood transplantation in relapsed acute myeloid leukemia after bone marrow transplantation.
    Kamitani I; Saito T; Yokoyama H; Nakano A; Ishii H; Tanoue S; Hattori D; Oshima S; Ishii S; Gunji T; Fukushima R; Katsube A; Shimada T; Nishiwaki K; Dobashi N; Yano S
    J Infect Chemother; 2021 Apr; 27(4):639-641. PubMed ID: 33214069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L.
    Wang X; DeFilippis RA; Weldemichael T; Gunaganti N; Tran P; Leung YK; Shah NP; Li HY
    Eur J Med Chem; 2024 Jan; 264():115977. PubMed ID: 38056299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
    Weis TM; Marini BL; Bixby DL; Perissinotti AJ
    Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gilteritinib: A Review in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukaemia.
    Kang C; Blair HA
    Target Oncol; 2020 Oct; 15(5):681-689. PubMed ID: 32940858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RNA-based
    Cucchi DGJ; Denys B; Kaspers GJL; Janssen JJWM; Ossenkoppele GJ; de Haas V; Zwaan CM; van den Heuvel-Eibrink MM; Philippé J; Csikós T; Kwidama Z; de Moerloose B; de Bont ESJM; Lissenberg-Witte BI; Zweegman S; Verwer F; Vandepoele K; Schuurhuis GJ; Sonneveld E; Cloos J
    Blood; 2018 May; 131(22):2485-2489. PubMed ID: 29669779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gilteritinib: First Global Approval.
    Dhillon S
    Drugs; 2019 Feb; 79(3):331-339. PubMed ID: 30721452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.
    Arrigo G; D'Ardìa S; Audisio E; Cerrano M; Freilone R; Giai V; Secreto C; Urbino I; Frairia C
    Acta Haematol; 2022; 145(5):566-570. PubMed ID: 35580565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Venetoclax Plus Gilteritinib for
    Daver N; Perl AE; Maly J; Levis M; Ritchie E; Litzow M; McCloskey J; Smith CC; Schiller G; Bradley T; Tiu RV; Naqvi K; Dail M; Brackman D; Siddani S; Wang J; Chyla B; Lee P; Altman JK
    J Clin Oncol; 2022 Dec; 40(35):4048-4059. PubMed ID: 35849791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study.
    Usuki K; Sakura T; Kobayashi Y; Miyamoto T; Iida H; Morita S; Bahceci E; Kaneko M; Kusano M; Yamada S; Takeshita S; Miyawaki S; Naoe T
    Cancer Sci; 2018 Oct; 109(10):3235-3244. PubMed ID: 30039554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of haploidentical hematopoietic stem cell transplantation on comutations based on next-generation sequencing in adult acute myeloid leukemia patients with the FLT3-ITD mutation.
    Tang F; Zhao X; Ruan G; Jiang Q; Jiang H; Xu L; Wang Y; Zhang X; Liu K; Huang X
    Hematol Oncol; 2023 Oct; 41(4):733-742. PubMed ID: 37272204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
    Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.